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Study protocol Fluid Lavage of Open Wounds (FLOW): design and 
rationale for a large, multicenter collaborative 2 × 3 
factorial trial of irrigating pressures and solutions 
in patients with open fractures
Flow Investigators
Abstract
Background: Open fractures frequently result in serious complications for patients, including infections, wound 
healing problems, and failure of fracture healing, many of which necessitate subsequent operations. One of the most 
important steps in the initial management of open fractures is a thorough wound irrigation and debridement to 
remove any contaminants. There is, however, currently no consensus regarding the optimal approach to irrigating 
open fracture wounds during the initial operative procedure. The selection of both the type of irrigating fluid and the 
pressure of fluid delivery remain controversial. The primary objective of this study is to investigate the effects of 
irrigation solutions (soap vs. normal saline) and pressure (low vs. high; gravity flow vs. high; low vs. gravity flow) on re-
operation within one year among patients with open fractures.
Methods/Design: The FLOW study is a multi-center, randomized controlled trial using a 2 × 3 factorial design. 
Surgeons at clinical sites in North America, Europe, Australia, and Asia will recruit 2 280 patients who will be centrally 
randomized into one of the 6 treatment arms (soap + low pressure; soap + gravity flow pressure; soap + high pressure; 
saline + low pressure; saline + gravity flow pressure; saline + high pressure). The primary outcome of the study is re-
operation to promote wound or bone healing, or to treat an infection. This composite endpoint of re-operation 
includes a narrow spectrum of patient-important procedures: irrigation and debridement for infected wound, revision 
and closure for wound dehiscence, wound coverage procedures for infected or necrotic wound, bone grafts or implant 
exchange procedures for established nonunion in patients with postoperative fracture gaps less than 1 cm, 
intramedullary nail dynamizations in the operating room, and fasciotomies for compartment syndrome. Patients, 
outcome adjudicators, and data analysts will be blinded. We will compare rates of re-operation at 12 months across 
soap vs. saline, low pressure vs. high pressure, gravity flow pressure vs. high pressure, and low pressure vs. gravity flow 
pressure. We will measure function and quality of life with the Short Form-12 (SF-12) and the EuroQol-5 Dimensions 
(EQ-5D) at baseline, 2 weeks, 6 weeks, 3 months, 6 months, 9 months, and 12 months after initial surgical management, 
and measure patients' illness beliefs with the Somatic Pre-Occupation and Coping (SPOC) questionnaire at 1 and 6 
weeks. We will also compare non-operatively managed infections, wound healing, and fracture healing problems at 12 
months after initial surgery.
Discussion: This study represents a major international effort to identify a simple and easily applicable strategy for 
emergency wound management. The importance of the question and the potential to identify a low cost treatment 
strategy argues strongly for global participation, especially in low and middle income countries such as India and China 
where disability from traumatic injuries is substantial.
Trial Registration: This trial is registered at ClinicalTrials.gov (NCT00788398).
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Background
Orthopaedic injuries represent 67% of injury admissions
to Canadian hospitals [1]. It is estimated that by 2020,
disability from traffic accidents (the major cause of frac-
tures) will rank in the top 3 of all causes of disability [2].
Orthopaedic injuries are even more common interna-
tionally. Accelerated urbanization and industrialization in
India and China, which represent 40% of the world's pop-
ulation, have resulted in an alarming increase in trau-
matic injuries. A vehicular accident is reported every
three minutes and a death every 10 minutes on Indian
roads. For every death, 3 patients survive and live with
disability [3].
Open fractures account for an estimated 250,000 frac-
tures in North America annually [4]. These open frac-
tures are often complicated by infections, wound healing
problems, and failure of fracture healing-many of which
necessitate a re-operation. Open fractures are designated
as surgical emergencies and require urgent treatment.
Infections can occur in up to 50% of open fractures that
are severe or bec ome grossly contamina t ed due to the
mechanism of their injury [5,6]. Infection can lead to
both wound and fracture healing delays [7]. The addi-
tional treatment required to manage infections, as well as
wound and bone healing complications, leads to
increased health care costs, and additional adverse
impact on patients' quality of life.
Current management of grossly contaminated fractures
includes careful handling of the damaged soft tissues, as
well as stabilization of the bone [8,9]. The single most
important surgical step in the initial management of open
fractures is a thorough irrigation and debridement
[4,9,10]. Removal of all contaminated tissue and foreign
matter is necessary to prevent infection, support wound
healing, and promote fracture healing. Surgeons accom-
plish debridement with careful removal of all visible
debris and necrotic tissue along with copious irrigation of
the wound. There is, however, currently no consensus
regarding the optimal approach to irrigating the wounds
during the initial operative procedure. Multiple options
exist for irrigation solutions and the delivery of fluids.
Experimental Studies Evaluating the Effect of High and Low 
Pressure Wound Irrigation
Advocates of high-pressure irrigation believe that higher
pressures optimally remove all particulate matter and
contamination [11-16]. Low pressure advocates believe
that low pressure irrigation may damage bone to a lesser
extent than high-pressure irrigation, thus preserving
bone architecture [14,17-22].
We have conducted a series of laboratory investigations
using in-vitro models of contaminated tibial shaft frac-
ture, rat models of fracture healing, and cell culture mod-
els of bone nodule formation. Our experimental data
suggests high pressure lavage may be more effective than
low pressure lavage for removing debris and bacteria
f r o m  c o n t a m i n a t e d  o p e n  w o u n d s  a f t e r  a  3  h o u r  d e l a y
[5,20,23]. However, this efficacy in removing debris and
bacteria comes at the expense of damage to the bone tis-
sue [18,20], bacterial propagation into the intramedullary
canal of the fractured bones [18], and promotion of stem
cell differentiation away from bone forming cells (osteo-
blasts) toward the adipocyte cell types [24]. These cellular
level effects also translate into a significant reduction in
in-vivo strength of fracture healing. Mechanical testing of
36 fractured rat femora after 3 weeks of healing revealed a
37% lower peak bending force and stiffness in animals
treated with high pressure irrigation compared to the low
pressure groups (p < 0.05) [17].
While findings are not always consistent [13,16], the
weight of experimental evidence suggests a trade off
between greater efficacy in removing particulate matter
and bacteria with high pressure irrigation with the disad-
vantage being the potential for bone damage, driving par-
ticulate matter deeper into bone and tissues and delaying
bone healing. The lack of compelling clinical evidence
suggests the need for a randomized controlled trial of
varying irrigating pressures in patients with open frac-
tures.
Experimental Studies Evaluating the Effect of Various 
Irrigating Solutions
The type of irrigating solution and its effect on the effi-
cacy of wound debridement remain controversial.
Although experimental studies have evaluated several
irrigation additives including antiseptics, antibiotics, and
surfactants (soap), few have revealed promise beyond the
current common standard solution--normal saline.
Experiments suggest antiseptics are toxic to the host
cells [4,25-29]. Although some investigators have pro-
moted irrigation with antibiotic solutions (such as baci-
tracin), concerns about allergic reactions [30], increased
cost [31], promotion of antibiotic resistance, and
unproven efficacy have limited their use [32]. In an in-
vitro study evaluating multiple irrigating solutions, expo-
sure of mouse calvarial cells to 10% ethanol, 10% povi-
done-iodine, 10% antimicrobial wash, or 4%
chlorhexidine gluconate resulted in cell-density decreases
of 70%, 63%, 70%, and 69% respectively [5]. Normal saline
solution or soap solutions were the only solutions that did
not significantly decrease the cell numbers when com-
pared with controls. The antimicrobial wash further led
to a significant decline in in-vitro bone formation (bone
nodule formed in-vitro) compared to saline solution [5].
Soaps may act as an emulsifier to help cleanse wounds.
Soaps are fatty acids with a positively charged tail and a
negatively charged carboxylate head. The positively
charged hydrocarbon tail is hydrophobic and repels  BMC Musculoskeletal Disorders 2010, 11:85
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water. The negatively charged carboxylate head is hydro-
philic and interacts with water. This unique property
allows for oils (dirt) to become suspended by forming
micelles which are easily washed away. As the soap-water
solution comes in contact with oil/dirt, the hydrophilic
carboxylate heads of the soap bond with water molecules,
while the hydrophobic hydrocarbon tails are attracted to
each other and to the dirt/oils. This leads to the forma-
tion of micelles with the hydrophobic hydrocarbon
chains and the trapped dirt on the inside and the hydro-
phobic carboxylate heads on the exterior of the spherical
surface. The negative charged carboxylate heads give the
micelles (which now have the dirt/oil trapped in the cen-
ter) a negative charge, which causes them to repel each
other and remains dispersed in the water. While sus-
pended, they can be washed away, theoretically cleansing
the wound.
We, along with other investigators, have shown in labo-
ratory and animal models that soap solution is more
effective in removing bacteria and particular matter from
wounds and bone than normal saline [5,10,26,33,34],
without toxic effects to soft tissues and bone [5]. We have
further shown a possible synergy between soap and low
pressure irrigation [5]. The use of a soap solution under
low pressure pulsatile irrigation removed the greatest
number of bacteria from the contaminated tibia when
compared to either the soap alone, or low pressure irriga-
tion with saline alone (p < 0.01) [5].
The potential efficacy of soap solution in removing par-
ticulate matter, oil and bacteria from contaminated open
wounds requires confirmation in a definitive trial. At
pennies per application, soap offers a low cost, globally
applicable, simple intervention that may reduce infec-
tions, as well as wound and bone healing complications
following open fractures.
Inconclusive Clinical Evidence
Soap solution has been evaluated by a single surgeon in a
randomized trial of 400 patients with 458 open fractures
[31]. At a mean 1.3 year follow up, soap solution (80 mL
per 3L bag of normal saline) demonstrated a trend
towards a decreased risk of infection compared to an
antibiotic solution (100,000 U of bacitracin per 3L normal
saline) (13% vs. 18%, relative risk 0.74, 95% confidence
interval 0.45-1.26, p = 0.2). The study reported a signifi-
cant reduction in wound healing complications with soap
compared to antibiotic (4% vs. 9.5%; p = 0.03). While this
study provides some support for the efficacy of soap solu-
tion, its findings are limited by relatively small sample
size, lack of generalizability to other centers or countries,
unconvincingly concealed randomization, and unblinded
non-independent adjudication of the primary outcome.
A recent randomized controlled trial of 21 patients
with traumatic open wounds [15] compared two alterna-
tive high pressure irrigating devices, one delivering 40
p.s.i. and the other delivering above 5,000 p.s.i. pressure
to the wound. The investigators reported a similar effi-
cacy in both high pressure devices. This very small study
provides limited data suggesting that irrigation pressures
of 40 p.s.i. or greater provide similar efficacy to higher
pressures; the relative effect of lower pressure irrigation
(less than 40 p.s.i.) remains unaddressed.
Multinational Survey: Uncertainty Regarding Optimal 
Management, and Support for a Large Trial
We have conducted two surveys [24,35] to explore sur-
geons' views regarding wound irrigation. Of 577 ortho-
p a e d i c  s u r g e o n s  m a n a g i n g  o p e n  t i b i a l  f r a c t u r e s  w h o
responded to our first survey, 39% preferred high and
45% low-pressure irrigation in their treatment of open
wounds [24].
We mailed our second survey to members of the Cana-
dian Orthopaedic Association and delivered it to attend-
ees of an international fracture course (AO, Davos,
Switzerland) [35]. Of the 1,764 surgeons who received the
questionnaire, 984 (55.8%) responded. In the manage-
ment of open wounds, 676 (70.5%) favoured normal
s al ine  a lo ne . O nl y 12 s ur g eons  ( 1.3% ) r ou ti ne ly used a
soap solution. Although the majority of surgeons [695
(71%)] preferred what they called "low pressure" when
delivering the irrigating solution to the wound, there was
considerable variation in what pressures constituted high
versus low pressure lavage. Based upon the definitions
provided, the majority (63.7%) were actually delivering
what would constitute "high" irrigating pressures to the
wound. In summary, current practice reflects the use of
normal saline and higher irrigating pressures [35].
Of the respondents, 803 (84.8%) supported a clinical
trial evaluating outcomes following the use of different
irrigating solutions and 730 (77.6%) supported a trial of
irrigating pressures. Most surgeons [889 (94.2%)]
reported they would change their practice if a large RCT
showed a clear benefit of an irrigating solution. The
majority of surgeons [765 (80.6%)] believed that a partic-
ular irrigating solution would need to reduce the risk of
infection compared to a standard by at least 25% to
change practice. As a final confirmation of support, 612
surgeons reported they would participate in a random-
ized trial to resolve the controversy [35].
Pilot Randomized Trial
We have successfully completed a pilot RCT using a fac-
torial design to assess the feasibility of the proposed
definitive FLOW trial. One hundred and eleven patients
with open extremity fractures were randomized in per-
muted blocks using a customized web-based/telephone
randomization system, to receive either soap or saline
solution and either low or high pressure irrigation.  BMC Musculoskeletal Disorders 2010, 11:85
http://www.biomedcentral.com/1471-2474/11/85
Page 4 of 14
Patients, outcome assessors and data analysts were
blinded to treatment allocation. The primary outcomes of
the pilot study were the rates of reoperation to treatment
infection, non-union, and would healing problems in
open fracture wounds. Our pilot study demonstrates: 1)
our ability to recruit patients for the definitive trial; 2)
investigators' compliance with key aspects of the proto-
col; 3) maintenance of data quality; 4) maintenance of
high follow up rates; 5) our ability to organize trial proce-
dures (randomization, data management) in a multina-
t i o n a l  t r i a l ;  6 )  T h e  s t u d y  r e s u l t s  a r e  c o n s i s t e n t  w i t h  a
possible benefit of soap and low pressure irrigation. We
have also used the pilot to develop and revise Case Report
Forms (CRFs) and the Manual of Operations for Investi-
gational Sites for the pivotal FLOW trial.
Study Objectives
The objectives of this study are to determine the effects of
irrigation solutions (soap vs. normal saline) and irrigation
pressures (gravity flow vs. high; low vs. high; gravity flow
vs. low) on open fractures of extremities. The primary
objective is to determine, in patients operatively treated
for open fractures of the extremity, the effects of irriga-
tion solutions (soap vs. normal saline) and irrigation pres-
sures (high vs. low; high vs. gravity flow; low vs. gravity
flow) on re-operations within one year after initial sur-
gery. The secondary objective is to investigate the impact
of irrigation solution (soap vs. normal saline), pressure
(high vs. low; high vs. gravity flow; low vs. gravity flow),
and illness beliefs on patient function and quality of life at
one year. We will also compare non-operatively managed
infections, wound healing, and fracture healing problems
within 12 months after initial surgery.
Methods and Design
Overview of Study Design
This study is a multi-center, blinded, randomized con-
trolled trial, using a 2 × 3 factorial design. Patients are
randomized to one of 6 treatment arms: 1) castile soap
solution and low pressure, 2) castile soap solution and
high pressure, 3) castile soap solution and gravity flow
pressure, 4) saline solution and low pressure, 5) saline
solution and high pressure, and 6) saline solution and
gravity flow pressure (Table 1). We have chosen a facto-
rial design to optimize the efficiency and reduce overall
trial cost [36,37]. We will be able to efficiently and simul-
taneously investigate two interventions (irrigating pres-
sure and irrigating solution) by including all participants
in both analyses. For instance, when analyzing the effect
of soa p solution versus saline, we will include pa tien ts
across different pressure groups (including gravity flow,
low pressure, and high pressure); in the comparison of
high versus low pressure, we will include patients using
soap solution and saline. The United States Department
of Defense-OETRP grants review committee urged us to
include a very low pressure group (gravity flow irrigation)
arm to maximize the applicability of the trial, and we have
done so. The Research Ethics Board at each clinical site
has approved the protocol.
Randomization
We will randomize patients using variable block sizes to
ensure effective stratification. An automated internet-
based randomization system based at the CLARITY
Methods Center at McMaster University (available 24
hours/day), which we have used successfully for other
multicenter trials, will ensure concealed randomization
of eligible consenting patients. To ensure a prognostic
balance between key factors, we will stratify patients by
center and the type of Gustilo-Anderson open fracture
(Types I and Type II versus Type III). We will apply per-
muted randomization, using block sizes of 6 or 12 at ran-
dom, to allocate patients.
Once patients or their proxy have provided informed
consent and the operating or attending surgeon has eval-
uated the open fracture wound, the investigator or desig-
nated study team member will contact the automated
randomization system at the Methods Center. Patients
will be randomized to one of 6 treatment groups: 1) cas-
tile soap solution and low pressure, 2) castile soap solu-
tion and high pressure, 3) castile soap solution and
gravity flow pressure, 4) saline solution and low pressure,
5) saline solution and high pressure, and 6) saline solution
& gravity flow pressure.
Patient Selection
Patients who meet the eligibility criteria outlined below
are to be included in the FLOW study. Only one fracture
per patient is to be included. For patients with multiple
eligible open fractures, the study fracture will be the most
severe (i.e. the greatest Gustilo-Anderson Type).
Eligibility Criteria
Eligible patients will meet all the following inclusion cri-
teria: 1) men or women who are 18 years of age or older,
2) adequate x-ray confirmation of an open fracture, 3)
open fractures (Gustilo-Anderson Types I-IIIB) (Table 2),
and 4) fracture requiring operative fixation.
We will exclude patients meeting any of the following
criteria: 1) open fractures with an associated vascular def-
icit (Gustilo-Anderson type IIIc), 2) known allergy to
detergents or castile soap ingredients, 3) previous wound
infection or history of osteomyelitis in the injured
extremity, 4) previous fracture with retained hardware in
injured extremity that will interfere with new implant fix-
ation, 5) surgical delay to operative wound management
greater than 24 hours from hospital admission, 6) use of
immunosuppressive medication within 6 months, 7)
immunological deficient disease conditions (e.g. HIV), 8)  BMC Musculoskeletal Disorders 2010, 11:85
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fracture of the hand (metacarpals and phalanges), 9) frac-
ture of the toes (phalanges), 10) likely problems, in the
judgment of the investigators, with maintaining follow-
up, 11) previous randomization in this study or a compet-
ing study , 12) patient is a prisoner or is at high risk of
incarceration during the follow-up period (clinical sites
located outside of the United States may enroll prisoners
or those at high risk of incarceration with the approval of
their local IRB/REB), and 13) failure to obtain informed
consent.
Patient Recruitment and Screening
Figure 1 shows the patient identification and screening
procedures. Informed consent will be obtained from all
eligible patients. If a patient is deemed unable to consent
due to being temporarily incapacitated (i.e. due to
trauma, pharmacological or other influence), informed
consent may be obtained from the patient's legally autho-
rized representative. When the patient is deemed no lon-
ger incapacitated, the patient will be approached
regarding the study and informed consent will be
obtained from the patient for ongoing participation in the
study. If the patient declines continued participation, the
patient will be withdrawn from the study.
We will register all patients who meet the eligibility cri-
teria and document reasons for failure to randomize. We
will document all patients screened for eligibility and
record patients as: 1) eligible and included, 2) eligible and
missed, and 3) excluded. The blinded Central Adjudica-
tion Committee (CAC) will adjudicate all situations
where eligibility is in doubt.
Study Interventions
Irrigating Solutions
Patients will be randomized to have their open fracture
wound irrigated with either soap or normal saline. In the
operating room, surgeons will use sterile technique to
inject 80 mL of the clear liquid soap (Castile Soap, Triad
Medical Inc. Franklin, Wisconsin - 17% concentration in
de-ionized water preserved in 90 mL bottles) with a ster-
ile syringe into a 3L bag of normal saline. Our choice of
castile soap and dosing is based upon experimental evi-
dence, a recent clinical trial that used this formulation
without adverse effects [31], and our pilot study that con-
firmed its safety. Patients randomized to the normal
saline group (control) will receive sterile normal saline
provided in 3L bags.
We will standardize the minimum amount of soap or
saline solution based upon the severity of open fracture
wound according to the Gustilo-Anderson Classification
(Type I - 3 Litres, Types II and III - 6 Litres). We based
these volumes on our international survey data [35] to
reflect current standards and management protocols.
Irrigating Pressures
Patients will also be randomized to have the solutions
delivered to the open fracture wound by gravity flow (1-2
p.s.i.), low-pressure irrigation (5-10 p.s.i.), or high-pres-
Table 1: 2 × 3 Factorial Design with a Total of 2280 Patients and 380 Patients per Arm
Gravity Flow 
Pressure
Low Pressure High Pressure Total
Soap solution 380 380 380 1140
Saline 380 380 380 1140
Total 760 760 760 2280
Table 2: Gustilo-Anderson Classification of Open Fractures
Open 
fracture type
Characteristics
Type I Clean wound smaller than 1 cm in diameter, simple 
fracture pattern, no skin crushing.
Type II A laceration larger than 1 cm but without significant 
soft tissue crushing, including no flaps, degloving, or 
contusion. Fracture pattern may be more complex.
Type III An open segmental fracture or a single fracture with 
extensive soft tissue injury. Also included are injuries 
older than 8 hours. Type III injuries are subdivided 
into three types.
Type IIIA Adequate soft tissue coverage of the fracture 
despite high energy trauma or extensive laceration 
or skin flaps.
Type IIIB Inadequate soft tissue coverage with periosteal 
stripping. Soft tissue reconstruction is usually 
necessary.
Type IIIC Any open fracture that is associated with an arterial 
injury that requires repair.  BMC Musculoskeletal Disorders 2010, 11:85
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Figure 1 Trial Conduct Procedure.
Patient Recruitment, Randomization and Surgical Interventions 
Identification of Patients                  Direct referral-within center  Data Collected
                                                             
Assessment of       Study explanation
Patient Eligibility History-review eligibility criteria, Screening Form
and other relevant medical conditions
Physical Examination     
Radiographs
Informed Consent, if eligible Informed  Consent
   All eligible patients who consent to the trial
Randomization 24 hour web-based or telephone  Baseline Form
Eligibility criteria reviewed again Randomization 
Key patient information recorded Form    
Randomization issued to patient
Surgery Either high, low or gravity flow     Surgical Form
                       with soap solution or saline solution
                       Surgical protocols will be followed
Follow Up Schedule
1 Week Assessment of outcome events Follow-Up Form
SF-12, EQ-5D, SPOC
2 Weeks Assessment of outcome events Follow-Up Form
SF-12, EQ-5D 
6 Weeks Assessment of outcome events Follow-Up Form
SF-12, EQ-5D, SPOC
3 Months Assessment of outcome events Follow-Up Form
SF-12, EQ-5D
6 Months Assessment of outcome events     Follow-Up Form
SF-12, EQ-5D
9 Months Assessment of outcome events Follow-Up Form
SF-12, EQ-5D
  
12 Months Assessment of outcome events Follow-Up Form
SF-12, EQ-5D
* Follow Up Form includes antibiotic use, AEs, SAEs, infections, reoperations, protocol deviations or wound 
healing problems, and appropriate forms.  BMC Musculoskeletal Disorders 2010, 11:85
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sure irrigation (>20 p.s.i.) with a battery operated irriga-
tor [Stryker Surgilav or Zimmer Pulsavac Plus].
Gravity flow irrigation will be standardized across par-
ticipating centers as 3L bags of normal saline (alone or
with soap solution) suspended 6-8 feet above floor level
(2-5 feet above the table) using an I.V. pole. Irrigation tub-
ing (measuring 1/4 - 3/8 inch inner diameter) will be con-
nected to the 3L bag and secured with a stopcock (or
compressive device) until ready for use. At the time of
irrigation, the stopcock (or compression device) will be
released and gravity flow irrigation of the open wound
will occur. A large basin collecting the runoff will be suc-
tioned by standard intraoperative suction tubing. No
pressure will be applied to the bag of solution.
To ensure standard low and high pressure delivery, we
will require the irrigator to be one of two devices [Stryker
Surgilav or Zimmer Pulsavac Plus] at all participating
sites. For low pressure delivery, the high flow trauma tip
of the Stryker Surgilav (at the low pressure setting) or the
shower tip of the Zimmer Pulsavac Plus (at the low pres-
sure setting) will be used to deliver a pressure of 6 p.s.i or
5.8 p.s.i, respectively. For the high pressure delivery, the
multi-orifice tip of the Stryker Surgilav (at the high pres-
sure setting) or the shower tip of the Zimmer Pulsavac
Plus (at the high pressure setting) will be used to deliver a
pressure of 30 p.s.i or 23 p.s.i., respectively. The irrigator
t i p  w i l l  b e  h e l d  p e r p e n d i c u l a r  t o  a n d  5  c m  a b o v e  t h e
wound.
Standardization of Procedures and Peri-Operative Care
We will standardize key aspects of peri-operative care
and technical aspects of the initial irrigation and debride-
ment procedure.
Antibiotics
Pre-operative I.V. antibiotics will be administered com-
mencing on diagnosis. Postoperative, I.V. antibiotics will
be administered for at least 24 hours post-surgery. Spe-
c i f i c  a n t i b i o t i c s  w i l l  b e  u s e d  a t  t h e  d i s c r e t i o n  o f  t h e
attending surgeon. The recommended guidelines include:
Cephalosporin (Ancef) I.V. for Grade I-II injuries, Cepha-
losporin (Ancef) I.V. and Aminoglycoside (Gentamycin)
I.V. for Grade III injuries, and Cephalosporin (Ancef) I.V.,
Aminoglycoside (Gentamycin I.V) and penicillin for gross
contaminated injuries. For large open wounds (Types III),
temporary local antibiotic administration will be permit-
ted (bead pouch) until definitive wound closure. All anti-
biotics that are prescribed for the randomized fracture
are to be recorded on the CRFs.
Wound Management
Prior to randomization, we will record whether the
attending surgeon plans to use antibiotic beads or antibi-
otic osteobiologics and if the attending surgeon plans to
use negative pressure wound therapy (wound vacs) to
treat the patient's randomized open fracture wound. The
FLOW randomization system will capture this informa-
tion prior to the treatment allocation being provided.
Since the attending surgeons will not be blinded to the
treatment allocation and bias may be introduced, we
strongly encourage surgeons to use antibiotic beads or
antibiotic osteobiologics, and negative pressure wound
therapy (wound vacs) only if they indicated this prior to
randomization. We will record the actual use of antibiotic
beads or antibiotic osteobiologics and negative pressure
wound therapy (wound vacs) on the case report forms
and we will document any discrepancies with the initial
plan.
Intra-operatively, surgeons will prepare and drape the
injured extremity using sterile technique. Iodine-based or
chlorhexidine-based initial wound scrubs will be allowed
for extremity preparation. Surgeons will initially remove
all gross debris, contaminants, and dead tissue (muscle,
fat, fascia, skin, or bone). Adequacy of the debridement
will be judged by colour, consistency, contractility, and
bleeding of the muscle as well as complete eradication of
contaminated and necrotic tissue including nonarticular
devitalized bone. Delayed wound closure, split thickness
skin grafting, or muscle flaps should occur by 7-14 days
following the initial surgery when possible. Surgeons will
repeat the irrigation and debridement procedure until the
open wound is clean and soft tissues viable. Patients will
receive the same irrigating pressure and solution to which
they were initially randomized for all subsequent irriga-
tions and debridements.
Fracture Stabilization
Fracture stabilization will be at the surgeon's discretion.
Surgeons should stabilize the fractures using current best
practices. These include the following guidelines: 1)
definitive fixation should be in place by 14 days from the
initial operative wound irrigation and debridement as
soft tissue allows, 2) temporizing fracture stabilization
(external fixation) for grossly contaminated (Type II or
Type III) wounds if used should be spanning external fix-
ation outside the zone of the injury, 3) definitive fixation
for shaft fractures of the lower extremity will include stat-
ically locked intramedullary nails (unless very proximal
or very distal) [23], and 4) upper extremity fractures
should be treated when possible with plates and screws
[38]. Due to the varying nature of these traumatic frac-
tures, each fracture should be stabilized as the treating
surgeon sees fit. To ensure both feasibility and generaliz-
ability, we will not standardize the implants.
Study Endpoints
Primary Study Endpoints
The primary study endpoint is re-operation within 12
months post initial surgery to treat an infection, manage
a wound healing problem, or promote fracture healing.
Re-operation is defined as a surgery that occurs subse-
quent to the initial procedure. This composite endpoint  BMC Musculoskeletal Disorders 2010, 11:85
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of re-operation will include a narrow spectrum of patient-
important procedures: irrigation and debridement for
infection, revision and closure for wound dehiscence,
wound coverage procedures for infected or necrotic
wounds, bone grafts or implant exchange procedures for
established nonunion in patients with postoperative frac-
ture gaps less than 1 cm, intramedullary nail dynamiza-
tions in the operating room, and fasciotomies for
compartment syndrome.
Infections will be classified according to the Center for
Disease Control (CDC) Criteria [39]. We will define
infection in patients as a constellation of clinical symp-
toms and laboratory examinations. These will include
(but are not limited to) fever, erythema/cellulitis, positive
tissue cultures, and frank purulent drainage.
Our definition for wound healing problems will follow
previously published criteria [31]. Any re-operations
related to problems with primary wound healing will be
documented. These include: 1) a dehiscence of a suture
line, death of a flap or graft, or failure to heal which is not
due to underlying deep infection (drainage of purulent
fluid and positive cultures) or 2) problems with second-
ary healing that include failure of the wound to progress
to satisfactory closure (wound becomes larger over time,
failed granulation, or development of necrosis all requir-
ing further intervention).
Diagnosis of nonunion will include a failure of the frac-
ture to progress towards healing as observed by the treat-
ing surgeon and that requires further intervention to
promote healing either surgical (i.e. bone graft) or non-
surgical (i.e. bone stimulator). Final consensus on non-
u n i o n  w i l l  b e  d e t e r m i n e d  b y  t h e  C e n t r a l  A d j u d i c a t i o n
Committee.
The following conditions are not considered outcome
events: 1) planned secondary interventions from initial
surgical procedures and 2) any re-operations to promote
fracture healing in patients with post-operative fracture
gaps greater than 1 cm.
Secondary Study Endpoints
The secondary study endpoints include patient function
and quality of life measured by the Short Form-12 (SF-12)
and the EuroQol-5 Dimensions (EQ-5D), non-operatively
managed infections, wound healing problems, and frac-
ture healing problems within 12 months.
Adjudication of Study Events
The Central Adjudication Committee, blinded to treat-
ment allocation, will adjudicate re-operations to treat
infection, wound healing problems, or fracture healing
problems (delayed unions and nonunions), soft tissue
procedures without infection in patients who have under-
gone more than 3 re-operations, and non-operatively
managed infections, wound healing problems, and frac-
ture healing problems. The adjudicators may review the
patient's initial hospital notes, clinic notes, and x-rays.
Study Follow-Up
Figure 1 shows the study follow-up timeline. At each fol-
low up, patient conditions and outcomes will be
recorded. At 1 and 6 weeks, patients will also complete
the the Somatic Pre-Occupation and Coping (SPOC)
questionnaire. The SPOC questionnaire is a validated
self-administered, 27-item questionnaire that measures
patient's illness beliefs.
Any adverse events, re-operations, infections, wound
healing problems, antibiotic use relating to the fracture,
and protocol deviations will be recorded. Missed follow
up or early withdrawal will also be documented.
We will withdraw patients only if patients withdraw
consent for participation. We will document the reasons
for patient withdrawal from the trial. For those patients
who withdraw from other study activities, we will seek
their approval to collect clinical data from their medical
and hospital charts, and/or to contact them by telephone
to ask about the primary and secondary outcomes.
Protecting Against Sources of Bias
Patients, outcome adjudicators, and data analysts will be
blinded to the study treatment. The operating room team
(including the surgeon and study coordinator) cannot be
blinded since the equipment they use for the irrigation
pressures and the solutions are readily distinguishable.
We will implement several procedures to limit loss of fol-
low up (Figure 2). Patients who do not receive the irriga-
t i o n  s o l u t i o n  a n d / o r  p r e s s u r e  t o  w h i c h  t h e y  a r e
randomized will be followed as per the study protocol.
Co-interventions and Contaminations
To minimize the co-interventions, we will standardize the
peri-operative procedures and antibiotics use. Patients
will receive the surgical management to which they are
randomized for the initial irrigation and debridement and
for all subsequent irrigation and debridements. To pre-
vent any patients from receiving the wrong solution or
pressure, the following three measures will be applied
whenever possible: 1) FLOW posters with clear prepara-
tion guides will be posted in all emergency operating
rooms, 2) soap bottles will be placed in all orthopaedic
operating rooms in clearly marked boxes with instruc-
tions, and 3) surgeons who complete the subsequent irri-
gation and debridements will be aware of the patient's
treatment allocation. The study coordinator of the clini-
cal site will, if possible, be present during any subsequent
irrigation and debridements to ensure that patients
receive the treatment to which they are randomized.
Statistical Plan
Sample Size Determination
Our sample size is chosen to identify if there is any differ-
ence in effects of pairwise comparisons of the three irri-
gation pressure groups (high vs. low; high vs. gravity flow;  BMC Musculoskeletal Disorders 2010, 11:85
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low vs. gravity flow) on re-operations at 12 months (Table
1). This sample size will also allow us to establish if there
is a difference between soap and saline (see below). For
the comparisons of the three different pressures, we have
chosen a two-sided alpha level of 0.05. Given that this
applies to three pairwise comparisons, our alpha level for
each individual comparison will be, according to Tukey's
method, 0.0188 [40].
Our best estimate of the control group re-operation
rate is 30%. In a previous randomized trial that involved
lower limb open fractures [31], the overall rate of re-oper-
ations due to infection, wound healing complications and
delayed fracture healing was 46%. In the SPRINT trial,
the reoperation rate in 400 patients with open tibial frac-
tures was 27% (95%CI: 22-31). In the FLOW pilot study,
which was conducted mainly in North America, the reop-
eration rate in 111 patients with open fractures was 23%
(95% CI 16%-32%). In this pivotal study, we expect that
the reoperation rates will be higher in the international
sites in India and China. A 25% relative risk reduction
associated with one or both of the lower pressures is
plausible based on the pilot data. Furthermore, based
upon our survey 80% of surgeons will consider a 25% rel-
ative difference between treatments important enough to
change practice [35]. We anticipate 5% of patients will be
lost to follow up given the results of pilot study.
Our experiences in the pilot study, and with centers
that have committed to participate in the FLOW defini-
tive study, suggest that we will be able to recruit a total
sample size of 2280, 760 per pressure group at the margin
of table for a 2 × 3 factorial design (i.e. 380 per cell, Table
1). Table 3 shows our study power for the three pairwise
Figure 2 Strategies to Limit Loss to Follow-Up.
1) Individuals should be excluded if they are likely to present problems with follow-up (refer to 
exclusion criteria).  
2) At the time of randomization, as well as their own address and telephone number, each patient 
should provide the name and address of their primary care physician, and the name, address and 
phone number of three people at different addresses with whom the patient does not live with 
who are likely to be aware of the patient’s whereabouts. The research coordinator should confirm 
that these numbers are accurate prior to the patient’s discharge from hospital.   
3) Whenever possible, participants should be given information on open extremity fractures, their 
complications and the potential treatment effects, expectations for personal benefit from study 
participation, and be encouraged for adherence with follow-up visits and research protocols.   
 
4) The Study Coordinator should remind patients of upcoming clinic visits.   
5) Study coordinator should contact patients no less than once every three months to maintain 
contact and obtain information about any planned change in residence.   
6) If a patient refuses to return for a follow-up assessment, study surgeons and coordinator should 
determine his/her status with regard to revision surgery or any secondary outcome by phone 
contact with the patient or the patient’s family physician   BMC Musculoskeletal Disorders 2010, 11:85
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comparisons of alternative pressures given our chosen
sample size and given varying control event rates and rel-
ative risk reductions. Power is over 80% for relative risk
reductions over 28% for control event rate as low as 25%.
Power is over 80% for relative risk reduction as low as
24% if our control event rate is as high as 30%.
W e have the same best estimate of control group re-
operation rate (i.e. 30%) for the saline solution effect,
based on two randomized trials [31,35]. Given that our
pilot data suggested a 37.5% relative risk reduction with
soap versus saline, a relative risk reduction of 25% is plau-
sible. For the saline versus soap comparison, we will have
a larger number of patients (i.e. 1,140) per group and a
higher threshold p-value (0.05 vs. 0.018). Therefore, for
any given baseline risk and relative risk reduction, our
power will be greater for the saline-soap comparison than
for the pressure comparisons.
For our secondary outcomes, we consider an important
difference in SF-12 to correspond to a moderate effect as
reported by Cohen [41] as well as a minimally important
difference in the SF-12 as reported by Ware [42]. In both
cases, the value is 1/2 the standard deviation, equivalent
to 5 point difference in score. Specifying an alpha level =
0.01, a beta = 0.20 (study power = 0.80), we require a sam-
ple of at least 405 patients (135 per pressure group at the
margin of the table) to ensure detection of a 1/2 standard
deviation improvement.
The EQ-5D correlates well with the Health Utilities
Index (HUI) and both have been reported to provide sim-
ilar estimates of utility [43]. Drummond et al [44] report
that 0.03 - 0.04 incremental changes in HUI represent a
patient-important difference. For adequate study power,
we will need to recruit at least 329 patients per group at
the margin of the table (alpha level = 0.01, a beta = 0.20,
difference = 0.04, σ = 0.15). Thus, in all circumstances,
our desired sample size of 2280 patients (760 per group at
the margin of the table) will be sufficient to detect the
minimally important differences in our secondary mea-
sures of outcome.
Statistical Methods
Primary Analysis
Analyses will include all patients in the groups to which
they were randomized. The data analyst and investiga-
tors, while conducting the analyses, will be blind to treat-
ment groups. We will use the log-rank test and the
Kaplan-Meier survival curve to compare the main effects
of irrigating solution (soap vs. saline) and irrigation pres-
sure (high vs. low, high vs. gravity flow, low vs. gravity
flow) at the margins of the 2 × 3 factorial design on time
to the first re-operation after the initial surgery. We will
use a two-sided alpha level of 0.05 for the comparison of
irrigation solution and a two-sided alpha level of 0.0188
for pairwise comparison of irrigation solution. We will
use Cox model to generate hazard ratio and its associated
95% confidence intervals for each comparison. The analy-
ses will be stratified by center and the type of Gustilo-
Anderson open fracture (Types I and II versus Type III).
Adjusted analyses, employing Cox regression, will
examine and control for the influence of patient and sur-
gical factors that might be associated with the risk of re-
operation, including age, degree of soft tissue injury,
upper or lower extremity injury, extent of fracture gap,
type of internal fixation, and severity of fracture.
Secondary Analyses
We will also examine the interaction of soap with pres-
sure by including the main effects and their interaction
Table 3: The Power of Our Study to Detect the Relative Risk Reduction for Pairwise Comparison of Three Pressure Groups 
Given Varying Control Event Rate
Relative risk reduction
20% 24% 28% 32% 35%
Control event 
rate
25% 0.49 0.68 0.84 0.93 0.97
27% 0.54 0.73 0.87 0.95 0.98
30% 0.61 0.80 0.92 0.98 0.99
33% 0.68 0.85 0.95 0.99 1.00
35% 0.72 0.89 0.99 1.00 1.00
* Note: We use a two-sided alpha level of 0.0188 for each pairwise comparison of three pressure groups, and the sample size per group at the 
margin is 760 (380 per cell).  BMC Musculoskeletal Disorders 2010, 11:85
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terms in the Cox regression with the outcome variable as
re-operation. This secondary analysis will have lower
power and only large effects will be detectable.
In addition to re-operation, we will also compare the
effects of irrigation solution (soap vs. saline) and pressure
(low vs. high; gravity flow vs. high; gravity flow vs. low)
on the component outcomes, including non-operatively
treated fracture healing complications, wound healing
problems, and infection (deep and superficial), using log-
rank test and Kaplan-Meier survival curve. Adjusted
analyses, using the Cox model, will be used to examine
and control for the influence of patients and surgical fac-
tors.
We will employ the generalized linear model for
repeated-measure analysis of variance to examine the
effects of time, treatment, and the interaction between
the two to compare functional status and quality of life
for all comparison groups. We will construct multi-vari-
able regression models to explore the association
between SPOC scores and functional outcome at 1-year,
as measured by SF-12 physical component summary
(PCS) and mental component summary (MCS) scores.
We will also examine if SPOC scores at 1 and 6 weeks are
similarly predictive.
Subgroup Analyses
We plan to conduct two subgroup analyses, both with
strong biological rationale and possible interaction
effects. The first will compare hazard ratios of re-opera-
tion based upon the degree of soft tissue injury (Gustilo-
Anderson Type I/II open fractures vs. Gustilo-Anderson
Type IIIA/B open fractures). The second will compare
hazard ratios of re-operation between fractures of the
upper and lower extremity. We will test if the treatment
effects differ with fracture types and extremities by put-
ting their main effect and interaction terms in the Cox
regression. For the comparison of pressure, we anticipate
that the low/gravity flow will be more effective in the
Type IIIA-B open fracture than in the Type I/II open frac-
ture, and be more effective in the upper extremity than
the lower extremity. For the comparison of solution, we
anticipate that soap will do better in the Type IIIA-B open
fracture than in the Type I/II open fracture, and better in
the upper extremity than the lower extremity.
Interim Analysis
We will conduct an interim analysis to monitor the treat-
ment benefits. The interim analysis will be performed
when two-thirds of the entire patient follow-up is com-
pleted (i.e. 1520 person-years). At this point, 91.7% (1886)
patients will have been recruited into the trial.
We use the O'Brien-Fleming Method to calculate the
stopping boundary. We will maintain the overall specified
type I error rate of 0.05 for the comparison of soap solu-
tion versus normal saline, and the threshold 2-sided sig-
nificance level is 0.012 for the interim analysis. We will
maintain the overall specified type I error of 0.0188 for
each of the three pairwise comparisons of irrigation solu-
tions, and the threshold 2-sided significance level is
0.003.
The data analyst will present the results of analysis,
including confidence intervals, to an independent DMC.
No one other than committee members will be aware of
the data on which the committee makes its decision, and
no one involved in the study will be aware of the content
of their deliberations.
Ethical Considerations
This study is to be conducted according to US and inter-
national standards of Good Clinical Practice (FDA Title
21 part 312 and International Conference on Harmoniza-
tion guidelines), applicable government regulations and
Institutional research policies and procedures. All
patients for this study will receive a consent form describ-
ing this study and providing sufficient information for
patients to make an informed decision about their partic-
ipation. The consent form has been submitted with the
protocol for review and approval by the Research Ethics
Board (REB) or Institutional Review Board (IRB) for each
clinical study site. The formal consent of a patient, using
the REB or IRB-approved consent form, will be obtained
before that patient undergoes any study procedure.
Discussion
Orthopaedic trials have been typically single-center, small
studies that often lack sufficient power to reliably evalu-
ate the important treatment effects, and suffer from
methodological weakness. Previous orthopaedic trials
have also tested only a single surgical intervention per
study. The FLOW trial is the first study in orthopaedic
traumatic surgery that uses a factorial design to address
the treatment effects of two interventions in a single trial.
Subsequent to our first large randomized orthopaedic
trial (SPRINT) that has set a benchmark of conducting
orthopaedic trials [45,46], the FLOW study, which will be
the largest trial in orthopaedic surgery, represents our
continuing efforts to test surgical interventions and
advance research methods in orthopaedic trials.
Our trial will test whether the soap solution and lower
irrigation pressure (i.e. gravity flow) reduce the risk of re-
operation. These strategies are easily applicable and asso-
ciated with minimal costs. Establishing their effects will
have potentially important clinical and economic impli-
cations, in particular to patients in low and middle
income countries such as India and China where disabil-
ity from traumatic injuries is substantial.
The FLOW trial has several important strengths. It will
enroll 2280 open fracture patients from clinical sites in
North America, Australia, Europe, and Asia - a sample
size that ensures sufficient power to reliably detect small
but important differences. Our trial uses the factorial  BMC Musculoskeletal Disorders 2010, 11:85
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design to simultaneously address effects of irrigation
solutions and pressures, which improves the efficiency of
the evaluation and substantially reduces the trial costs.
Our trial has set stringent methodological safeguards
against bias. We employ a variable block size with a cen-
tralized system to randomize patients; we will blind
patients, outcomes adjudicators, and data analysts to
treatment allocations; we will standardize peri-operative
care and wound management strategies to reduce co-
interventions; we will implement strategies to limit the
patients lost to follow up; and we will adjudicate the
events and address patient eligibility when in doubt
through a central adjudication committee.
One major limitation of FLOW is the fact that surgeons
cannot be blinded to treatment allocation, leaving the
assessment of outcomes and decisions to re-operate vul-
nerable to bias. To limit such bias, we are using an objec-
tive primary outcome and centrally adjudicating all
primary outcome events by a group of orthopaedic
trauma surgeons blinded to treatment allocation. The
primary composite outcome of re-operation provides a
patient-important estimate of effect superior to previ-
ously described measures such as radiographic fracture
healing, delayed unions, and nonunions.
FLOW, as for any trial evaluating two procedures
requiring surgical experience, is at risk for differential
expertise bias [47]. The procedures for irrigation and
debridement, however, are minimally technically chal-
lenging. It is unlikely that a substantial difference of
expertise is present across operative surgeons. We have
standardized peri-operative and wound management
procedures that are able to limit the differential use of
interventions.
The effects of irrigation strategies on open fractures
remain controversial. Prior evidence has suggested
potential benefits of soap solution and lower irrigation
pressures that have reduced costs. Identifying effective
treatment alternatives that reduce both the risk of subse-
quent operation and health care costs will have an impor-
tant contribution to orthopaedic practice. This trial will
not only potentially change current orthopaedic practice,
but also advance research methods for future orthopae-
dic trials.
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